Podcasts about Janssen

Cam Janssen, born in St. Louis and raised in Eureka, Missouri is the first ever born-and-raised St. Louisan to suit up in the NHL. He was famous for the rough stuff in hockey, and takes great pride in it. He spent several seasons exciting the crowds at the Enterprise Center. Cam has a great way of telling a story…Enjoy!

Antwerp trok naar Jan Breydel zonder Janssen, zonder Foulon, zonder uitfans… maar kwam wel terug mét een mirakel. In een match waar alle sterren verkeerd stonden, pakte de Great Old toch drie heerlijke punten mee naar 't Stad. In aflevering 492 blikken Pieter, Dirk en Dave terug op een onverwachte zege, een debuterende coach die nooit verliest, jonge gasten die het verschil maken, een penalty die nog lang zal nazinderen en een aanval die misschien wel de schoonste van het seizoen was.We hebben het over tactiek, lef, Harouns wisselbeleid, hoop voor de toekomst én… Paal Binnen numero 8 is te koop! De bestellink vind je op devierkantepaal.be! Host: Pieter VerhoevenGasten: Dave Van Meel en Dirk PietersMontage: Thomas Slembrouck#ad - Onze maandsponsor Studio of Stories heeft de droom om ooit een ceremonie op de Bosuil te mogen leiden... Heb jij plannen in die richting? Contacteer hem via deze link en gebruik code 'DVP26' voor 10% korting!https://bit.ly/4akD49u Hosted on Acast. See acast.com/privacy for more information.

God's Word helps us truly believe in Him that we may find true life in Him.

Rechte Straftaten von jungen Menschen haben in den letzten Jahren deutlich zugenommen. Ein Grund sind die vielen Krisen, mit denen Jugendliche konfrontiert sind, sagt Ausstiegsberaterin Lena Janssen. Die Entwicklung im Westen wird dabei unterschätzt. Janssen, Lena www.deutschlandfunkkultur.de, Interview

Het is een druk jaar voor Marc. Bier brouwen, podcasts maken en performen in het theater. Om de schwung erin te houden moet je jezelf af en toe belonen. Daar hebben we het over. Gelukkig lonkt de Kerstvakantie. Twee weken niets. Juan heeft iets lekkers meegenomen. Hacker-Pschorr Kellerbier. Der Himmel Der Bayern staat er op het flesje. Als het water je dan niet in de mond begint te lopen...In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

Ben Ennis and Brent Gunning wrap up the morning by speaking with Sportsnet.ca's Luke Fox about the Toronto Maple Leafs. They discuss expectations for Brad Treliving's media availability, the impact of David Kämpf, and the toll of injuries on the team. They also speculate on the return of Auston Matthews and whether the Leafs might have missed their championship window. After the break, former NHL player Cam Janssen (25:50) shares his insights on the Leafs and St. Louis Blues, including concerns about Mitch Marner's absence and Craig Berube's coaching status. Ben and Brent conclude with the Crown Royal Canadian moment.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliate.

In der neuen Folge hat sich unser Host Stephan Heßeling Stefan Janssen von der Rheinischen Post eingeladen. Das heutige Thema ist "Vom Stadion in die Zeitung".Schaltet ein und freut euch auf diese ganz besondere Folge!Das Beste daran: Bei Spotify könnt ihr jetzt sogar dem Gespräch zuschauen!

Warum brennen Brennnesseln? Ole spricht im Kinderpodcast „Ole schaut hin“ mit dem Moderator und Synchronsprecher Julian Janssen, besser bekannt als Checker Julian.

(CERTAIN INFORMATION NOT AVAILABLE TO THE PUBLIC)Canadian Patent No. 2,655,335 (“'335 Patent”), which was issued to Janssen Pharmaceutica N.V. for INVEGA SUSTENNA, involves a suspension of paliperidone palmitate for the treatment of schizophrenia and related disorders. The '335 Patent teaches a dosing regimen to achieve an optimum plasma concentration-time profile. Its claims have been construed in previous litigation and are not in issue: Janssen Inc. v. Teva Canada Ltd., 2020 FC 593,; Janssen Inc. v. Pharmascience Inc., 2022 FC 62, aff'd 2024 FCA 10 (“PMS Paliperidone”)). Its disclosure indicated that “[t]hose of ordinary skill in the art will understand that the maintenance dose may be [adjusted] up or down in view of patients condition (response to the medication and renal function)”.Pharmascience Inc. has served two Notices of Allegation in respect of pms-PALIPERIDONE PALMITATE, its proposed generic version of INVEGA SUSTENNA. In 2020, Janssen's infringement action related to Pharmascience's Abbreviated New Drug Submission No. 236094 was discontinued on consent. Shortly thereafter, Pharmascience served a Notice of Allegation and Detailed Statement in respect of a different Abbreviated New Drug Submission — No. 244641 — seeking approval to market and sell doses of pms-PALIPERIDONE PALMITATE. Janssen again commenced an infringement action under s. 6(1) of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133. In that proceeding, Pharmascience moved for summary trial. It was found that if Pharmascience's pms-PALIPERIDONE PALMITATE was made, constructed, used or sold as set out in the Abbreviated New Drug Submission, it would influence prescribers to prescribe the dosing regimen claimed in the '335 Patent, leading to direct infringement: PMS Paliperidone. The defence of invalidity went forward, with Janssen seeking a declaration that Pharmascience would infringe the '335 Patent if it were to make, use or sell pms-PALIPERIDONE PALMITATE in 50, 75, 100 and 150 mg doses.The Federal Court found that the Patent was not invalid based on obviousness or for lack of patentable subject matter. The claims provided specified dosing regimens meant to produce a concentration of the medication within the therapeutic range. If a physician chose to use a dose other than that claimed, to stop treatment or to change therapies, they would no longer be practicing the claimed invention. The Court of Appeal dismissed Pharmascience's appeal, finding that the use of the invention did not require the exercise of skill and judgment. Argued Date 2025-10-09 Keywords Intellectual property — Patents — Validity — Lack of patentable subject matter — Method of medical treatment — Vendible product — Skill and judgment — Fixed or variable dosing regimen — Canadian Patent No. 2,655,335 teaches dosing regimen that includes first loading dose, second loading dose and monthly maintenance doses — Regimen incorporates dosing windows of +/- 2 days for the second loading dose and +/- 7 days for the maintenance doses — Whether patent is invalid in that it claims an unpatentable method of medical treatment. Notes (Federal) (Civil) (By Leave) (Sealing order) (Certain information not available to the public) Language English Audio Disclaimers This podcast is created as a public service to promote public access and awareness of the workings of Canada's highest court. It is not affiliated with or endorsed by the Court. The original version of this hearing may be found on the Supreme Court of Canada's website. The above case summary was prepared by the Office of the Registrar of the Supreme Court of Canada (Law Branch).

Elias Janssen is one of the stars of the new Netflix film IN YOUR DREAMS which is out today! The animated film is fun for the whole family and Gavin got to sit down with him to talk about the process and what it was like, as well as his personal life and career.

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

No other book has had such a vast and formative effect on the history of the world as the Holy Bible.

Juan maakt zich zorgen. Dagelijks ziet hij studenten die constant zijn gefixeerd op hun mobiel. Het hangt als een soort mistlaag tussen elke sociale interactie in. Maar met de komst van Sora 2 schijnt er een waterig zonnetje op al dat intensieve social media gebruik.Marc heeft iets bijzonder (zwaars) meegenomen. Jopen Zwarte Ziel.  Dit bier heeft 385 dagen gerijpt op Woodford Bourbon Barrels. Spannend!In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

Discover the joy of generosity and worship as we explore Philippians 4:14–20 together. When we give for God's purposes, it brings Him joy and draws us closer to His heart. We don't have to fear letting go—God promises to supply all our needs according to the riches of His glory. Be inspired to live open-handed, trusting fully in the One who provides.

Do you know that you are also God's provision to others?

Janssen, Ingo www.deutschlandfunkkultur.de, Studio 9

Today we celebrate and remember the saints that have gone before us.Sunday service times are 9 a.m., 11 a.m., and 4 p.m. at the Mission Campus in Prairie Village, Kansas, and 10 a.m. at the Antioch Campus in Overland Park, Kansas. If you are unable to attend in person, you can worship online at villagepres.org/online. Support the showContact Village Presbyterian Churchvillagepres.orgcommunications@villagepres.org913-262-4200Have a prayer request? pastoral-care@villagepres.orgFacebook @villagepresInstagram @villagepreschurchYouTube @villagepresbyterianchurchTo join in the mission and ministry of Village Church, go to villagepres.org/giving

Recorded Live at One Heart Church (Port Lincoln) at the 9am service on the 26th of October 2025

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Scripture calls us not only to believe in Christ, but to actively participate in His mission—joyfully stewarding our resources to advance the good news. As we give, serve, and stand firm in faith, may our partnership bear lasting fruit and bring glory and praise to God. Join us as we reflect on Paul's letter to the Philippians and discover what it truly means to be partners in the Gospel.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

ASHP's senior education director Cindy Von Heeringen is joined by Lisa Janssen Carlson, IDS manager, and Craig Michael, data science pharmacist, both from the University of California, San Francisco as they discuss their upcoming Midyear session that focuses on incorporating AI in current pharmacy practice settings to enhance or streamline workflows.   The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, Viktor Grünwald shares his journey through a remarkable career in oncology, his focus on urogenital cancers, and his hopes for the future of cancer treatment. From reflections on research to European Society for Medical Oncology (ESMO) 2025 predictions and the promise of precision medicine, Grünwald offers an insightful look at evolving therapies and the pursuit of higher cure rates.  Timestamps:   00:00 – Introduction  01:03 – Reflections on his career  02:06 – Balancing research, clinical duties, and teaching  03:10 – Specialising in urogenital cancers  04:50 – Viktor's hobbies and interests  05:47 – Current landscape of genitourinary cancers  09:09 – Treatment modalities  11:09 – The CLEAR study  12:54 – European Society for Medical Oncology (ESMO) 2025 predictions  15:57 – The potential of precision medicine  19:09 – Viktor's three wishes for healthcare     Disclosure: Grünwald has received honoraria from Bristol Myers Squibb, Ipsen, Eisai, MSD Oncology, Merck Serono, AstraZeneca, Advanced Accelerator Applications (acquired by Novartis), Astellas Pharma, Amgen, Johnson & Johnson/Janssen, Telix Pharmaceuticals, Gilead Sciences, and Roche; research funding from Amgen, MSD Oncology, Bristol Myers Squibb, Seattle Genetics (now Seagen; acquired by Pfizer), Ipsen, Gilead Sciences, Bicycle Therapeutics, Exelixis, Novartis, Roche, and Johnson & Johnson/Janssen, with payment to the institution; travel/accommodation/expenses from Pfizer, Janssen, Merck Serono, Ipsen, and Amgen; and held consulting or advisory roles for Bristol Myers Squibb, Pfizer, Novartis, MSD Oncology, Ipsen, Janssen-Cilag, Eisai, Debiopharm, Gilead Sciences, Oncorena, Synthekine, and Recordati.  The CLEAR study was sponsored Eisai and Merck Sharp & Dohmre. 

Jacqueline (https://jacquelinejanssen.com/) has turned all she has learned about mental illness from her son's mental health journey into incredible advocacy. Her latest book, Every Homeless Person Has a Mother, chronicles Jacqueline's experience as a parent of an adult child with schizoaffective disorder. Jacqueline's son's battle with mental illness started when he was 19 years old. Jacqueline talks about the myriad of therapies and treatments her son received and how he ultimately ended up homeless as a result of anosognosia (https://www.nami.org/about-mental-illness/common-with-mental-illness/anosognosia/) or the lack of ability to recognize and treat his mental illness. Jacqueline has been a tireless advocate for families through her own work and with NAMI (https://www.nami.org/) and encourages families to get involved in their local NAMI chapters. Jacqueline emphasizes that when a loved one is incapable of making decisions for his or her own good, HIPAA (https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html) allows mental health providers to talk to families. Jacqueline also discusses strategies for reunification of families if there is estrangement due to mental illness. Jacqueline graciously shares many resources with listeners:Family Rights and HIPAA Facts: https://drive.google.com/file/d/1W6DO-beIMgMww0xH1QTUBECiSXd85W8H/view?usp=drive_link; HIPAA Decision Tree: https://drive.google.com/file/d/1DsI-DpSCFrZLfgCknTqjaMqXTavh0AGu/view?usp=drive_link; Family Involvement Accelerates Recovery: https://drive.google.com/file/d/1IoCvWj7H56K-F4qtSL5hiGHriEn6Nk8U/view?usp=drive_link; Every Homeless Person Has A Mother: https://everyhomelesspersonhasamother.substack.com; https://www.nationalshatteringsilencecoalition.org/; What I Wish I'd Known: https://drive.google.com/file/d/1KnkPLJKF7TCNyvTwxgnZIhtAcDOCgoYQ/view?usp=drive_link

This program, led by Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children's Practice, focused  on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. This accredited CME program provides healthcare professional with timely and practical education on fibrodysplasia ossificans progressiva (FOP). It is supported by an educational grant from Ipsen Biopharmaceuticals.To obtain CME credit, visit https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pediatrics, rheumatology, genetics, family medicine, and orthopedics. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Apply best practices for suspecting and diagnosing FOP.List best practices for managing young children with FOP.Identify best practices to manage older children and adults with FOP.Christiaan Scott, Professor of Medicine, University of OttawaRaphaella Stander, MBCHB, Pediatrician, Atlantic Children's PracticeDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses the following relevant financial relationships with ineligible companies:Grant/Research Support: Regeneron*, Incyte*, Janssen*, Roche*; Speaker's Bureau:  Ipsen*, Regeneron*, Springer*, Jannsen**Relationships have endedDr. Stander has no relevant financial relationships with ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Jesus is better than anyone or anything else—more worthy, more powerful, more compassionate. Because of His unmatched greatness, we are called to respond with faith, endurance, and heartfelt praise.

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE, offer a clear and practical way to work with unwholesomeness and support wholesomeness.

Note: This is the Free Content version of the interview with Tjalling Janssen. The full interview can be accessed as a Tier 2 Patreon member, or purchased for a one-time fee. More information at www.patreon.com/RejectedReligion. Tjalling is a PhD researcher at the Center for History of Hermetic Philosophy and Related Currents (HHP), based at the University of Amsterdam. His research interests include intermediary beings, magic, alchemy and Paracelsianism, and the reception of these subjects in (early to late) modernity. He investigates these topics from an environmental perspective as well as through social categories like class. His doctoral project entails an environmental reception history of the concept of elemental beings from the sixteenth to the early twentieth century, through its manifestations in magic, alchemy, literature, mining and agriculture. In this episode, we explore the shifting terrain of magical contact—where spirits, nature, and power intersect. Drawing from his article “Encounters, Evocations and Elemental Beings”, we'll trace the philosophical and esoteric implications of two very different modes of engaging with the unseen: Paracelsus's reverent encounters with elemental beings, and Dr. Rudd's ritual evocations. Along the way, we'll unpack the role of monsters, the ethics of spiritual mediation, and the deeper question of whether esotericism must rest on a singular, perennial foundation—or whether it can evolve, diversify, and apply to new contexts like ecology, psychedelics, tulpas, and even extraterrestrial contact. This is a conversation about relational knowing, cultural consciousness, and the future of interdisciplinary esoteric research.I have one correction to mention beforehand; Tjalling made a mistake in his wording when he mentioned the text De Meteoris (which comes up in the discussion), in his haste to explain the temporal trajectory. In all texts before De Meteoris elemental beings have souls. They are soulless from De Meteoris onwards, but that text lacks the possibility for elemental beings to acquire souls through marriage. The Liber de nymphis introduces that, and thus fulfills the implications of reciprocity and immanence (the “seeking out” or initiation of contact) that are absent from De Meteoris. PROGRAM NOTES Correspondences Journal Volume 12, no. 1 (2024)Encounters, Evocations and Elemental Beings Primary Source: A Book On Nymphs, Sylphs, Pygmies, and Salamanders, and On The Other Spirits (Paracelsus, Henry E. Sigerist) | PDF Secondary Sources: The Monsters of Paracelsus | Beasts, Humans, and Transhumans in the Middle Ages and the Renaissance [Abstract] Cultural History Of The Four Elements Contact Information: Tjalling D. Janssen - University of AmsterdamInstagram Theme Music and Editing: Daniel P. SheaEnd Production: Stephanie Shea

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE.

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE.

Become a Client: https://nomadcapitalist.com/apply/ Get our free Weekly Rundown newsletter and be the first to hear about breaking news and offers: https://nomadcapitalist.com/email Join us for the next Nomad Capitalist Live event: https://nomadcapitalist.com/live/ We are joined from the Nomad Capitalist stage by geopolitics expert Cyrus Janssen. Together with our very own Javier Carrea, he sits down for a chat on one of the most important countries in today's global landscape. The red giant, China. From how Chinese citizens define freedom differently from their Western counterparts, to the ongoing Nvidia chip saga and the Trump trade wars, they dive into everything you need to know about what might soon become the biggest economy in the world. Nomad Capitalist helps clients "go where you're treated best." We are the world's most sought-after firm for offshore tax planning, dual citizenship, international diversification, and asset protection. We use legal and ethical strategies and work exclusively with seven- and eight-figure entrepreneurs and investors. We create and execute holistic, multi-jurisdictional Plans that help clients keep more of their wealth, increase their personal freedom, and protect their families and wealth against threats in their home country. No other firm offers clients access to more potential options to relocate to, bank in, or become a citizen of. Because we do not focus only on one or a handful of countries, we can offer unbiased advice where others can't. Become Our Client: https://nomadcapitalist.com/apply/ Our Website: http://www.nomadcapitalist.com/ About Our Company: https://nomadcapitalist.com/about/ Buy Mr. Henderson's Book: https://nomadcapitalist.com/book/ Disclaimer: Neither Nomad Capitalist LTD nor its affiliates are licensed legal, financial, or tax advisors. All content published on YouTube and other platforms is intended solely for general informational and educational purposes and should not be construed as legal, tax, or financial advice. Nomad Capitalist does not offer or sell legal, financial, or tax advisory services.

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center) While walking meditation often receives less attention than sitting meditation, it offers numerous benefits worth exploring. In this talk, we will go into the 'Walking Meditation' sutta, where the Buddha outlines five benefits of this practice. We'll conclude with a bonus benefit.

(Insight Meditation Society - Retreat Center) While walking meditation often receives less attention than sitting meditation, it offers numerous benefits worth exploring. In this talk, we will go into the 'Walking Meditation' sutta, where the Buddha outlines five benefits of this practice. We'll conclude with a bonus benefit.

(Insight Meditation Society - Retreat Center) After an introduction to metta meditation, a guided meditation which includes the categories of benefactor, self, dear friend and a neutral being.

(Insight Meditation Society - Retreat Center) After an introduction to metta meditation, a guided meditation which includes the categories of benefactor, self, dear friend and a neutral being.

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center)

Carlos is back with the soon-to-be Mrs. Janssen herself, Alexis Bellino! The Real Housewives of OC has been nothing short of explosive these past few weeks, and we are HERE for every twist. Carlos and Alexis are getting down to the truth… the naked (wasted) truth! It’s a big, messy game of he said, she said, Katie said, Kiki said… and yes, even Slade said. Where does Katie go from here? Tune in as Carlos and Alexis break it all down.See omnystudio.com/listener for privacy information.

This week on Everybody in the Pool, we're diving into ocean intelligence. Despite covering more than 70% of the Earth, the ocean remains one of the least understood parts of our climate system — and that knowledge gap has huge consequences for weather prediction, global commerce, and climate resilience.Our guest is Tim Janssen, co-founder and CEO of Sofar Ocean, a company building the world's largest privately deployed network of ocean sensors. Their inexpensive, solar-powered Spotter buoys collect real-time data on waves, weather, and water conditions — information that fuels better climate models, safer shipping routes, and more sustainable ocean economies.We talk about:The massive “ocean data gap” and why it hinders weather and climate forecastingHow Sofar's 2,500+ Spotter buoys are creating the largest private ocean sensor networkWayfinder, Sofar's “Google Maps for ships,” and how it saves fuel and cuts emissionsWhy more ocean intelligence is critical for industries from aquaculture to shippingPartnerships with researchers, governments, and nonprofits to democratize ocean dataThe bigger vision: turning ocean information into a foundation for climate solutionsFrom global trade to Pacific Island communities, ocean intelligence has the potential to save money, reduce emissions, and protect vulnerable coastlines. Janssen explains why data may be the most important climate solution of all.LINKS:Sofar Ocean: https://www.sofarocean.com/All episodes: https://www.everybodyinthepool.com/Subscribe to the Everybody in the Pool newsletter: https://www.mollywood.co/Become a member and get an ad-free version of the podcast: https://everybodyinthepool.supercast.com/Please subscribe and tell your friends about Everybody in the Pool! Send feedback or become a sponsor: in@everybodyinthepool.com Hosted on Acast. See acast.com/privacy for more information.